Capricor Therapeutics, Inc. (CAPR) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $26.40: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 7.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Elevated put/call ratio: 6.29; Below-average business quality.
Capricor Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell and exosome-based therapies for Duchenne muscular dystrophy, with its lead asset deramiocel under FDA BLA review with a PDUFA target action date of August 22, 2026.
Sell if holding. Engine safety override at $26.40: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 7.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Elevated put/call ratio: 6.29; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.6/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 63d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
About Capricor Therapeutics, Inc.
About Capricor Therapeutics, Inc.
Capricor Therapeutics has a single clinical asset approaching potential commercialization: Deramiocel, a cell therapy for Duchenne muscular dystrophy, with a Biologics License Application under FDA review and a PDUFA target action date of August 22, 2026. The HOPE-3 Phase 3 trial enrolled 106 participants across 20 U.S. clinical sites and reported in December 2025 that the primary PUL v2.0 endpoint achieved 54% slowing of disease progression (p=0.029) and the key cardiac endpoint of left ventricular ejection fraction achieved 91% slowing of decline (p=0.041). The company held approximately $318.1 million in cash as of December 31, 2025, with no approved products and no commercial revenue.
Capricor's revenue path depends entirely on FDA approval of Deramiocel and subsequent commercialization, for which Nippon Shinyaku Co., Ltd. holds exclusive distribution rights in the United States and Japan. Manufacturing relies on cardiosphere-derived cells isolated from donated human hearts, creating supply chain dependency on the availability of qualified donor hearts and other raw materials at the company's San Diego facility. The exosome platform (StealthX) is in a Phase 1 clinical study for a SARS-CoV-2 vaccine candidate sponsored by the National Institute of Allergy and Infectious Diseases, with final results expected in Q2 2026. Additional exosome therapeutic programs remain in discovery. Capricor has received approximately $600 million in cumulative funding since inception from equity financings, collaborations, grants, and government programs including NIAID, NIH, DoD, and CIRM.
Show full overview
The commercial timeline depends on a single FDA decision. The original BLA received a Complete Response Letter in July 2025 citing insufficient evidence of effectiveness; following a Type A meeting with the FDA in August 2025, Capricor submitted a Class 2 resubmission that was accepted with a new PDUFA of August 22, 2026. A second refusal or further delay would materially extend the funding runway requirement. In March 2026, additional HOPE-3 cardiac MRI data presented at the Muscular Dystrophy Association Clinical & Scientific Conference showed a statistically significant reduction in myocardial fibrosis, which may support the resubmission case.
See also: Healthcare · Biotechnology
From Capricor Therapeutics, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-06-10Recent Developments — Capricor Therapeutics, Inc.
Latest news
- NEWS HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $60 Price Target — benzinga May 13, 2026 positive
- NEWS Capricor Therapeutics Q1 2026 Earnings Call Transcript — benzinga May 12, 2026 positive
- NEWS Capricor Therapeutics Q1 EPS $(0.59) Misses $(0.50) Estimate — benzinga May 12, 2026 negative
- NEWS Earnings Scheduled For May 12, 2026 — benzinga May 12, 2026 neutral
- NEWS Capricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy — benzinga May 8, 2026 negative
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 5.2% daily ATR makes tight stops impractical. Position-size conservatively.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $26.40: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 7.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Elevated put/call ratio: 6.29; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $24.32. Score 4.6/10, moderate confidence.
Take-profit target: $47.08 (+81.0% upside). Prior stop was $24.32. Stop-loss: $24.32.
Quality below floor (1.2 < 4.0).
Capricor Therapeutics, Inc. trades at a P/E of N/A (forward -34.3). TrendMatrix value score: 9.0/10. Verdict: Sell.
15 analysts cover CAPR with a consensus score of 4.1/5. Average price target: $54.
What does Capricor Therapeutics, Inc. do?Capricor Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell and exosome-based...
Capricor Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell and exosome-based therapies for Duchenne muscular dystrophy, with its lead asset deramiocel under FDA BLA review with a PDUFA target action date of August 22, 2026.